COMPANY PROFILE

Rebiotix

Explore full profile

Development-stage biotechnology company focusing on the treatment of gi diseases by developing human microbiome

Roseville, United StatesFounded 2011Biotech & Life Sciences

Valuation $100–250M Last recorded · 2014

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Rebiotix

Rebiotix Inc., a clinical-stage biotechnology company, focuses on developing microbiota restoration therapies to treat gastrointestinal diseases. Operating in the healthcare and biotechnology market, Rebiotix serves patients suffering from conditions like Clostridium difficile infection, inflammatory bowel disease, and hepatic encephalopathy. The company’s core business model revolves around creating a new class of biologic drugs that harness the power of the human microbiome. By restoring a healthy gut microbiota, Rebiotix aims to provide effective treatments for diseases that are challenging to manage with traditional antibiotics. Revenue is generated through the development and commercialization of these innovative therapies, which are currently in various stages of clinical trials.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2011
Headquarters: Roseville, United States
Employees: 56
Open positions: None listed
Dealroom signal: 33.9/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Microbiome, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Apr 2018	$0	—	Undisclosed	—
CONVERTIBLE✓Equity / VC	Sep 2017	$8.5M	—	Undisclosed	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Rebiotix website traffic

Latest recorded traffic for Rebiotix is 70 monthly website visits, down 87.3% over the last three months. Rebiotix's team declined 34.9% over the past year.

Latest monthly visits70 3-month web change-87.3% 1-year team growth-34.9%

Monthly website visitsApr 2016–Mar 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GUGutCrineDevelops microbiome-derived peptide therapeutics to prevent and treat cardio-metabolic and age-related disorders	Rudegård, Denmark	Operational	3	$587K	$2.3M
BIBiomeBankA clinical stage biotechnology company developing microbial therapies	Adelaide, Australia	Operational
NSNimble ScienceNimble Science is a precision medicine company with a multi-omic data platform to transform GI Care from plate to bedside	Calgary, Canada	Operational
RORondinXSolutions in the microbiome therapeutic and companion diagnostic spaces	Tel Aviv-Yafo, Israel	Acquired
TCThe Akkermansia CompanyPostbiotic supplements for weight management and metabolic health	Mont-Saint-Guibert, Belgium	Acquired
ABAlveolus BioHarnessing the power of the microbiome for the prevention and treatment of lung disease	Boston, United States	Operational
MEMetagenomiDiscovering the next generation of gene-editing systems for use in treating genetic diseases	Emeryville, United States	Operational
USUute ScientificDeveloping microbiome science to improve human health	Lohja, Finland	Operational